Tonix Pharmaceuticals (TNXP) - 2025 Q1 - Quarterly Results

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate in development for prevention of kidney transplant rejectio ...